Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2012. The report details a specific share repurchase transaction executed on May 25, 2012, pursuant to shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,800,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,427.5 pence per share; lowest price paid was 1,409.0 pence per share.
- Treasury Holdings (Settled): 539,747,927 shares (9.70% of total issued share capital).
- Treasury Holdings (Including Unsettled): 545,147,927 shares (10.85% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,024,977,044 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,800,000 shares for Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior settled position to 10.85% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total cost of the 1,800,000 share repurchase based on the weighted average price between 1,409.0 and 1,427.5 pence.
- Confirm the impact of the 10.85% Treasury holding on earnings per share (EPS) calculations.
- Check subsequent filings for the settlement status of the shares purchased but not yet settled at the time of this report.
- Review the remaining authorization limit for share buybacks following this transaction.